Market Overview

UPDATE: Sterne Agee Resumes Greenway Medical Technologies at Underperform on Share Overvalue

Related GWAY
Market Wrap For Tuesday, September 24: Markets Go Parabolic
Mid-Afternoon Market Update: Carnival Sinks on Weak Guidance; Markets Go Into The Red

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Greenway Medical Technologies (NYSE: GWAY) with an Underperform rating and $5.00 price target.

In the report, Sterne Agee noted, “While Greenway Medical has achieved admirable success with the 5-10 doctor practices over the past 5+ years, as the average size of physician practices rises, we do not think the company possesses enough scale to convince enterprise-size physician practices to use the company's technologies/services. We believe consensus revenue and EBITDA estimates are too high and GWAY shares are overvalued. Re-initiate with an Underperform rating and $5 price target.”

Greenway Medical Technologies closed on Tuesday at $11.69.

Latest Ratings for GWAY

Sep 2013KeyBancDowngradesBuyHold
Sep 2013Raymond JamesDowngradesStrong BuyMarket Perform
Sep 2013William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for GWAY
View the Latest Analyst Ratings

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Initiation Analyst Ratings


Related Articles (GWAY)

View Comments and Join the Discussion!